15 August 2018
Visiongain’s new report Drug of Abuse Testing Market Report 2017-2027: Employment Testing, Random Testing, Reasonable Testing, Post-Accident Testing, Saliva, Breath, Urine, Blood, Hair, Sweat, Schools and Educational Institutes, Hospitals and Healthcare Units, Government and Private Departments and Others report indicates that the global drug of abuse testing market will see $5.9bn in spending in 2022.
The global drug of abuse testing market was valued at $4.4bn in 2016 and is projected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is dominated by the Employment Testing submarket which held 39.3% share of that market in 2016.
The lead analyst of the report said: “Factors driving the growth of drug of abuse testing market is the stringent government rules and awareness regarding harmful drugs. Increase in chronic diseases caused by drug abuse has also augmented the demand for drug of abuse testing in recent years. However, the lack of availability of devices with high accuracy can be one of the restraining factors for the growth of drug of abuse testing market.”
The 165-page report contains 78 tables and 71 figures that add visual analysis in order to explain the developing trends within the global drug of abuse testing market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments by type (Employment Testing, Random Testing, Reasonable Testing, Post-Accident Testing), sample type (Saliva, Breath, Urine, Blood, Hair, Sweat) and by application (Schools and Educational Institutes, Hospitals and Healthcare Units, Government and Private Departments and Others).
The 165-page report offers market forecasts for these regional and national markets: North America (the US and Canada), Latin America (Mexico, Brazil, Argentina), Europe (Germany, France, UK, Italy, Spain, Rest of Europe), APEJ (China, India, Australia, Rest of APEJ), MEA (GCC Countries, South Africa, Rest of MEA) and Japan
Moreover, our work discusses the leading companies in the drug of abuse testing market. This report discusses the drivers, restraints as well as porter’s five forces analysis of the global drug of abuse testing market
The report Drug of Abuse Testing Market Report 2017-2027: Employment Testing, Random Testing, Reasonable Testing, Post-Accident Testing, Saliva, Breath, Urine, Blood, Hair, Sweat, Schools and Educational Institutes, Hospitals and Healthcare Units, Government and Private Departments and Others report will be of value to anyone who wants to better understand the drug of abuse testing market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the drug of abuse testing market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.